Pharmacokinetic Properties of Lorcaserin in the Fed and Fasted State

Exclusion Criteria

• •1. Prior participation in any study of lorcaserin.
• •2. Clinically significant new illness in the 1 month before screening
• •3. Not suitable to participate in the study in the opinion of the Investigator including an existing physical or mental condition that prevents compliance with the protocol
• •4. History of any of the following cardiovascular conditions:
• •* Myocardial infarction (diagnosed by cardiac enzyme\[s\] and/or diagnostic ECG), CVA, TIA or RIND within 6 months of screening;
• •* Cardiac arrhythmia requiring medical or surgical treatment within 6 months of screening
• •* Unstable angina
• •* History of pulmonary artery hypertension
• •5. Positive result of HIV, hepatitis B or hepatitis C screens
• •6. Malignancy within 2 years of the screening visit (except basal cell or squamous cell carcinoma with clean surgical margins)
• •7. Initiation of a new prescription medication within 1 month prior to screening.
• •8. Recent history (within 2 years prior to the screening visit) of alcohol or drug/solvent abuse or a positive screen for drugs of abuse at screening.
• •9. Participated in any clinical study with an investigational drug, biologic, or device within 1 month prior to screening
• •10. Use of SSRIs,SNRIs, and other medications must meet the washout period.